The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy

Multiple sclerosis (MS) is a highly heterogeneous disease involving a combination of inflammation, demyelination, and CNS injury. It is the leading cause of non-traumatic neurological disability in younger people. There is no cure, but treatments in the form of immunomodulatory drugs (IMDs) are avai...

Descripción completa

Detalles Bibliográficos
Autor principal: Pachner, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495360/
https://www.ncbi.nlm.nih.gov/pubmed/36140203
http://dx.doi.org/10.3390/biomedicines10092099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495360/
https://www.ncbi.nlm.nih.gov/pubmed/36140203
http://dx.doi.org/10.3390/biomedicines10092099

Ejemplares similares